Esperion Announces a Featured Presentation in the Late Breaker/Featured Science Track and Three Poster Presentations Accepted for the 2024 American Heart Association (AHA) Scientific Sessions
Esperion (NASDAQ: ESPR) announced the acceptance of four presentations at the 2024 American Heart Association (AHA) Scientific Sessions in Chicago. The presentations include one featured presentation in the Late Breaker/Featured Science track focusing on bempedoic acid and limb outcomes in statin-intolerant patients with peripheral artery disease from the CLEAR Outcomes Trial. Additionally, three poster presentations will cover liver steatosis and cardiovascular events, statin intolerance effects on patient management, and real-world effectiveness of bempedoic acid plus ezetimibe therapy.
Esperion (NASDAQ: ESPR) ha annunciato l'accettazione di quattro presentazioni alle Sessioni Scientifiche della American Heart Association (AHA) 2024 a Chicago. Le presentazioni includono una presentazione in evidenza nel percorso Late Breaker/Featured Science che si concentra sull'acido bempedoico e sugli esiti agli arti nei pazienti intolleranti alle statine con malattia arteriosa periferica dallo studio CLEAR Outcomes. Inoltre, tre presentazioni poster tratteranno la steatosi epatica e gli eventi cardiovascolari, gli effetti dell'intolleranza alle statine sulla gestione dei pazienti e l'efficacia reale della terapia con acido bempedoico più ezetimibe.
Esperion (NASDAQ: ESPR) anunció la aceptación de cuatro presentaciones en las Sesiones Científicas de la Asociación Americana del Corazón (AHA) 2024 en Chicago. Las presentaciones incluyen una presentación destacada en la categoría de Late Breaker/Featured Science que se centra en el ácido bempedoico y los resultados en las extremidades en pacientes intolerantes a las estatinas con enfermedad arterial periférica del estudio CLEAR Outcomes. Además, tres presentaciones en póster cubrirán la esteatosis hepática y los eventos cardiovasculares, los efectos de la intolerancia a las estatinas en la gestión del paciente, y la efectividad en el mundo real de la terapia con ácido bempedoico más ezetimibe.
Esperion (NASDAQ: ESPR)는 시카고에서 열리는 2024 아메리칸 심장 협회(AHA) 과학 세션에서 네 개의 발표가 수락되었음을 발표했습니다. 이 발표 중 하나는 Late Breaker/Featured Science 분야에서의 주요 발표로, CLEAR Outcomes Trial에서 말초 동맥 질환이 있는 스타틴 불내성 환자의 사지 결과에 대한 벰페도익산의 효과를 중점적으로 다룹니다. 추가로, 세 개의 포스터 발표에서는 간 지방증 및 심혈관 사건, 환자 관리에서의 스타틴 불내성 효과, 그리고 벰페도익산과 에제티미브 치료의 실제 효과를 다룰 것입니다.
Esperion (NASDAQ: ESPR) a annoncé l'acceptation de quatre présentations lors des Sessions Scientifiques de l'American Heart Association (AHA) 2024 à Chicago. Les présentations incluent une présentation vedette dans la catégorie Late Breaker/Featured Science, qui se concentre sur l'acide bempédoïque et les résultats sur les membres chez des patients intolérants aux statines souffrant de maladies artérielles périphériques dans le cadre de l'essai CLEAR Outcomes. De plus, trois présentations sous forme de poster aborderont la stéatose hépatique et les événements cardiovasculaires, les effets de l'intolérance aux statines sur la gestion des patients, et l'efficacité dans la pratique de la thérapie combinant l'acide bempédoïque et l'ézétimibe.
Esperion (NASDAQ: ESPR) gab bekannt, dass vier Präsentationen bei den 2024 American Heart Association (AHA) Scientific Sessions in Chicago angenommen wurden. Die Präsentationen umfassen eine hervorgehobene Präsentation im Bereich Late Breaker/Featured Science, die sich auf Bempedoinsäure und die Ergebnisse an den Gliedmaßen bei mit Statinen intoleranten Patienten mit peripherer Arterienerkrankung aus der CLEAR Outcomes-Studie konzentriert. Darüber hinaus werden drei Posterpräsentationen die Lebersteatose und kardiovaskuläre Ereignisse, die Auswirkungen der Statintoleranz auf das Patientenmanagement und die Effektivität von Bempedoinsäure kombiniert mit Ezetimib in der Praxis behandeln.
- None.
- None.
ANN ARBOR, Mich., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that one featured presentation in the Late Breaker/Featured Science track and three poster presentations have been accepted for the AHA Scientific Sessions 2024 in Chicago, IL, November 16-18, 2024.
Featured Science
Bempedoic Acid and Limb Outcomes in Statin-Intolerant Patients with Peripheral Artery Disease: New Insights from the CLEAR Outcomes Trial
Featured Science: Vascular Outcomes in the Spotlight
November 18, 2024, 8 - 9:15 a.m. CST
Presenter: Marc P. Bonaca, MD, MPH, FAHA, FACC
Poster Presentations
Liver Steatosis and Liver Fibrosis Predict Major Adverse Cardiovascular Events in the CLEAR Outcomes Trial
Poster Presentation
CVD Science Smorgasbord II
Zone 3, Science & Technology Hall
November 16, 2024, 10:30 - 11:30 a.m. CST
Presenter: Diederick (Rick) Grobbee, MD, PhD, FESC
Statin Intolerance due to Muscle Symptoms Affects Management of Patients: Insights from the CLEAR Outcomes Trial
Moderated Digital Poster Presentation 15
Lipids and Management – A Deep Dive
Zone 3, Science & Technology Hall
November 16, 2024, 11:50 - 11:55 a.m. CST
Presenter: Ulrich Laufs, MD, PhD
Effectiveness of Lipid-lowering Therapy with Bempedoic Acid plus Ezetimibe in a Real-world Cohort
Moderated Digital Poster Presentation 1
Clinical and Translational Studies of Lipoproteins and Lipids in Vascular Diseases
Zone 1, Science & Technology Hall
November 16, 2024, 1:40 - 1:45 p.m. CST
Presenter: Evelyn Sarnes, PharmD
Esperion Therapeutics
At Esperion, we discover, develop, and commercialize innovative medicines to help improve outcomes for patients with or at risk for cardiovascular and cardiometabolic diseases. The status quo is not meeting the health needs of millions of people with high cholesterol – that is why our team of passionate industry leaders is breaking through the barriers that prevent patients from reaching their goals. Providers are moving toward reducing LDL-cholesterol levels as low as possible, as soon as possible; we provide the next steps to help get patients there. Because when it comes to high cholesterol, getting to goal is not optional. It is our life’s work. For more information, visit esperion.com and esperionscience.com and follow us on X at twitter.com/EsperionInc.
Esperion Contact Information:
Investors:
Alina Venezia
investorrelations@esperion.com
(734) 887-3903
Media:
Tiffany Aldrich
corporateteam@esperion.com
(616) 443-8438
FAQ
What presentations will Esperion (ESPR) showcase at the 2024 AHA Scientific Sessions?
When and where will Esperion (ESPR) present at the 2024 AHA Scientific Sessions?
What is the main focus of Esperion's (ESPR) featured presentation at AHA 2024?
